Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)

NCT02565186 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT02565186
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02565186 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
October 7, 2015
Completion date
August 20, 2019
Enrollment
2,171 (actual)
Sites
196

Conditions

As the registry lists them; a condition with its own page is linked.

migraine disorders